Predicting how HIV-1 may resist treatments to personalize care for patients
Predicting HIV-1 escape from therapeutics in vitro and in vivo - toward personalizing medicine for people living with HIV
['FUNDING_R01'] · UNIVERSITY OF IOWA · NIH-11056762
This study is looking at how changes in the HIV-1 virus can make it harder for certain treatments to work, so we can better predict which patients might need different therapies to improve their care.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF IOWA (nih funded) |
| Locations | 1 site (IOWA CITY, UNITED STATES) |
| Trial ID | NIH-11056762 on ClinicalTrials.gov |
What this research studies
This research investigates how mutations in the HIV-1 virus can lead to resistance against antiretroviral therapies. By analyzing the genetic sequences of the virus, the study aims to predict which patients are likely to develop resistance to specific treatments. The approach involves using advanced algorithms to forecast changes in the virus's proteins before treatment begins, allowing for more tailored therapeutic strategies. Ultimately, the goal is to improve treatment outcomes for individuals living with HIV by personalizing their care based on their unique viral characteristics.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals living with HIV who are starting or currently undergoing antiretroviral therapy.
Not a fit: Patients who are not living with HIV or those who have already developed significant resistance to all available antiretroviral therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for people living with HIV, reducing the risk of therapy resistance.
How similar studies have performed: Previous research has shown promise in using genetic sequencing to predict viral resistance, indicating that this approach could lead to significant advancements in personalized HIV treatment.
Where this research is happening
IOWA CITY, UNITED STATES
- UNIVERSITY OF IOWA — IOWA CITY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: HAIM, HILLEL — UNIVERSITY OF IOWA
- Study coordinator: HAIM, HILLEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome Virus